FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to an antibody-mediated biosensor containing a cell expressing a chimeric hybrid protein that contains an antibody-binding domain of the Fcγ-receptor, a transmembrane domain, and an alpha-immunoglobulin signaling domain, and can be used in medicine
EFFECT: resulting biosensor can be used to efficiently identify the target agent in the sample.
23 cl, 11 dwg, 1 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| 1E10 MONOCLONAL MOUSE ANTIBODY 1E10 AND RECOMBINANT CHIMERIC (MOUSE-HUMAN) ANTIBODY XI1E10, NEUTRALIZING BACILLUS ANTHRACIS LETHAL TOXIN, AND A STRAIN OF HYBRID CULTURED ABIMAL CELLS -MUS MUSCULUS 1E10 | 2020 |
|
RU2745116C1 |
| PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING MALIGNANT TUMOUR | 2016 |
|
RU2714205C2 |
| HIV-1 SUBTYPE A P17 PROTEIN ANTIBODIES | 2019 |
|
RU2727673C1 |
| BIOSENSOR SYSTEM FOR FAST DETECTION OF DETERMINED COMPONENTS | 2016 |
|
RU2717658C2 |
| METHOD OF PRODUCING PRECURSOR RENAL CELLS | 2016 |
|
RU2730861C2 |
| HERPES VACCINE | 2019 |
|
RU2731073C1 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2019 |
|
RU2781542C2 |
| CHO-SE-9/4 CELL STRAIN, PRODUCER OF CHIMERIC HUMAN ERYTHROPOIETIN ANTIBODY AND CHIMERIC ANTIBODY PRODUCED BY SAID STRAIN | 2019 |
|
RU2717038C1 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2017 |
|
RU2766586C2 |
| MATERIALS AND METHODS USED FOR TREATMENT OF RESPIRATORY DISEASES IN DOGS | 2020 |
|
RU2811752C2 |
